173 related articles for article (PubMed ID: 36799816)
1. Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer.
Cui M; Shoucair S; Liao Q; Qiu X; Kinny-Köster B; Habib JR; Ghabi EM; Wang J; Shin EJ; Leng SX; Ali SZ; Thompson ED; Zimmerman JW; Shubert CR; Lafaro KJ; Burkhart RA; Burns WR; Zheng L; He J; Zhao Y; Wolfgang CL; Yu J
Int J Surg; 2023 Feb; 109(2):99-106. PubMed ID: 36799816
[TBL] [Abstract][Full Text] [Related]
2. Association of Matrix Metalloproteinase 7 Expression With Pathologic Response After Neoadjuvant Treatment in Patients With Resected Pancreatic Ductal Adenocarcinoma.
Shoucair S; Chen J; Martinson JR; Habib JR; Kinny-Köster B; Pu N; van Oosten AF; Javed AA; Shin EJ; Ali SZ; Lafaro KJ; Wolfgang CL; He J; Yu J
JAMA Surg; 2022 Jul; 157(7):e221362. PubMed ID: 35612832
[TBL] [Abstract][Full Text] [Related]
3. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
4. [Value of endoscopic ultrasound-guided fine needle aspiration in pretest prediction and diagnosis of pancreatic ductal adenocarcinoma].
Wu L; Guo W; Li Y; Cheng T; Yao Y; Zhang Y; Liu B; Zhong M; Li S; Deng X; Zhu W
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Sep; 38(10):1171-1178. PubMed ID: 30377133
[TBL] [Abstract][Full Text] [Related]
5. Prognostic influence of endoscopic ultrasound-guided fine needle aspiration in IPMN-derived invasive adenocarcinoma.
Suzuki R; Irie H; Takagi T; Sugimoto M; Konno N; Sato Y; Watanabe K; Nakamura J; Marubashi S; Hikichi T; Ohira H
BMC Cancer; 2018 Oct; 18(1):974. PubMed ID: 30314433
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma.
Preis M; Gardner TB; Gordon SR; Pipas JM; Mackenzie TA; Klein EE; Longnecker DS; Gutmann EJ; Sempere LF; Korc M
Clin Cancer Res; 2011 Sep; 17(17):5812-21. PubMed ID: 21652542
[TBL] [Abstract][Full Text] [Related]
7. P53 immunolabeling in EUS-FNA biopsy can predict low resection rate and early recurrence in resectable or borderline resectable pancreatic cancer treated with neoadjuvant therapy.
Oshima M; Okano K; Kamada H; Suto H; Ando Y; Ibuki E; Ishikawa R; Masaki T; Haba R; Suzuki Y
J Hepatobiliary Pancreat Sci; 2023 Jun; 30(6):802-814. PubMed ID: 36448271
[TBL] [Abstract][Full Text] [Related]
8. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.
Taherian M; Wang H
Chin Clin Oncol; 2022 Jun; 11(3):21. PubMed ID: 35726190
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.
Murthy P; Zenati MS; Al Abbas AI; Rieser CJ; Bahary N; Lotze MT; Zeh HJ; Zureikat AH; Boone BA
Ann Surg Oncol; 2020 Mar; 27(3):898-906. PubMed ID: 31792715
[TBL] [Abstract][Full Text] [Related]
10. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
Nishiwada S; Sho M; Cui Y; Yamamura K; Akahori T; Nakagawa K; Nagai M; Nakamura K; Takagi T; Ikeda N; Li W; Baba H; Goel A
Int J Cancer; 2021 Feb; 148(3):769-779. PubMed ID: 32895958
[TBL] [Abstract][Full Text] [Related]
11. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma.
Zhang Y; Huang ZX; Song B
World J Gastroenterol; 2021 Jun; 27(22):3037-3049. PubMed ID: 34168406
[TBL] [Abstract][Full Text] [Related]
12. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A
Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476
[TBL] [Abstract][Full Text] [Related]
13. Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next-generation sequencing acquired by endoscopic ultrasound-guided FNA and FNB.
Gan Q; Roy-Chowdhuri S; Duose DY; Stewart JM; Coronel E; Bhutani MS; Lee JH; Weston B; Ge PS; Ross WA; Maitra A
Cancer Cytopathol; 2022 Apr; 130(4):275-283. PubMed ID: 34905283
[TBL] [Abstract][Full Text] [Related]
14. A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma.
Zhu L; Shen S; Wang H; Zhang G; Yin X; Shi X; Gao S; Han J; Ren Y; Wang J; Jiang H; Guo S; Jin G
BMC Cancer; 2023 Aug; 23(1):790. PubMed ID: 37612635
[TBL] [Abstract][Full Text] [Related]
15. Cytologic features and clinical implications of undifferentiated carcinoma with osteoclastic giant cells of the pancreas: An analysis of 15 cases.
Reid MD; Muraki T; HooKim K; Memis B; Graham RP; Allende D; Shi J; Schaeffer DF; Singh R; Basturk O; Adsay V
Cancer Cytopathol; 2017 Jul; 125(7):563-575. PubMed ID: 28371566
[TBL] [Abstract][Full Text] [Related]
16. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment.
Leonhardt CS; Pils D; Qadan M; Jomrich G; Assawasirisin C; Klaiber U; Sahora K; Warshaw AL; Ferrone CR; Schindl M; Lillemoe KD; Strobel O; Fernández-Del Castillo C; Hank T
Ann Surg; 2024 Feb; 279(2):314-322. PubMed ID: 37042245
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Biomarker Expression on Primary Pancreatic Ductal Adenocarcinoma Tissues Using Fine-Needle Biopsies: Paving the Way for a Patient-Tailored Molecular Imaging Approach.
Houvast RD; van Duijvenvoorde M; Chua J; Vankemmelbeke M; Durrant LG; Inderson A; van Hooft JE; Mieog JSD; Bonsing BA; Sier CFM; Crobach ASLP; Vahrmeijer AL; Kuppen PJK
Mol Diagn Ther; 2023 Mar; 27(2):261-273. PubMed ID: 36656512
[TBL] [Abstract][Full Text] [Related]
18. A microRNA-based test improves endoscopic ultrasound-guided cytologic diagnosis of pancreatic cancer.
Brand RE; Adai AT; Centeno BA; Lee LS; Rateb G; Vignesh S; Menard C; Wiechowska-Kozłowska A; Bołdys H; Hartleb M; Sanders MK; Munding JB; Tannapfel A; Hahn SA; Stefańczyk L; Tsongalis GJ; Whitcomb DC; Conwell DL; Morisset JA; Gardner TB; Gordon SR; Suriawinata AA; Lloyd MB; Wylie D; Labourier E; Andruss BF; Szafranska-Schwarzbach AE
Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1717-23. PubMed ID: 24662333
[TBL] [Abstract][Full Text] [Related]
19. ZIP4 is a novel diagnostic and prognostic marker in human pancreatic cancer: a systemic comparison between EUS-FNA and surgical specimens.
Xu C; Wallace MB; Yang J; Jiang L; Zhai Q; Zhang Y; Hong C; Chen Y; Frank TS; Stauffer JA; Asbun HJ; Raimondo M; Woodward TA; Li Z; Guha S; Zheng L; Li M
Curr Mol Med; 2014 Mar; 14(3):309-15. PubMed ID: 24345208
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive molecular profiling of pancreatic ductal adenocarcinoma in FNA, biopsy, and resection specimens.
Razzano D; Bouza SJ; Hernandez PV; Wang M; Robert ME; Walther Z; Cai G
Cancer Cytopathol; 2022 Sep; 130(9):726-734. PubMed ID: 35511415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
